Bamco Inc. NY Acquires 228,977 Shares of Inari Medical, Inc. (NASDAQ:NARI)

Bamco Inc. NY increased its holdings in Inari Medical, Inc. (NASDAQ:NARI) by 29.5% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 1,006,129 shares of the company’s stock after purchasing an additional 228,977 shares during the quarter. Bamco Inc. NY owned approximately 1.72% of Inari Medical worth $41,493,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Jennison Associates LLC grew its position in shares of Inari Medical by 63.2% in the 3rd quarter. Jennison Associates LLC now owns 1,576,641 shares of the company’s stock valued at $65,021,000 after buying an additional 610,468 shares during the last quarter. Vestal Point Capital LP boosted its holdings in Inari Medical by 342.9% in the third quarter. Vestal Point Capital LP now owns 1,550,000 shares of the company’s stock valued at $63,922,000 after acquiring an additional 1,200,000 shares during the last quarter. Point72 Asset Management L.P. boosted its holdings in Inari Medical by 113.3% in the second quarter. Point72 Asset Management L.P. now owns 1,481,283 shares of the company’s stock valued at $71,324,000 after acquiring an additional 786,691 shares during the last quarter. Armistice Capital LLC increased its position in Inari Medical by 353.1% during the 2nd quarter. Armistice Capital LLC now owns 1,009,252 shares of the company’s stock valued at $48,595,000 after purchasing an additional 786,501 shares during the period. Finally, American Century Companies Inc. raised its holdings in Inari Medical by 26.8% during the 2nd quarter. American Century Companies Inc. now owns 980,917 shares of the company’s stock worth $47,231,000 after purchasing an additional 207,485 shares during the last quarter. 90.98% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, CFO Mitch C. Hill sold 3,000 shares of the stock in a transaction dated Thursday, September 12th. The shares were sold at an average price of $45.13, for a total value of $135,390.00. Following the completion of the sale, the chief financial officer now owns 179,600 shares in the company, valued at $8,105,348. This represents a 1.64 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director William Hoffman sold 40,000 shares of the business’s stock in a transaction dated Wednesday, October 16th. The stock was sold at an average price of $45.02, for a total transaction of $1,800,800.00. Following the transaction, the director now owns 601,233 shares in the company, valued at approximately $27,067,509.66. This trade represents a 6.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 186,000 shares of company stock worth $8,990,990 in the last ninety days. Corporate insiders own 10.60% of the company’s stock.

Inari Medical Trading Up 0.4 %

Shares of NASDAQ:NARI opened at $52.12 on Tuesday. Inari Medical, Inc. has a 52-week low of $36.73 and a 52-week high of $67.13. The business’s 50 day simple moving average is $46.48 and its two-hundred day simple moving average is $47.58.

Analysts Set New Price Targets

NARI has been the topic of a number of analyst reports. Leerink Partners initiated coverage on shares of Inari Medical in a research note on Tuesday, September 3rd. They issued a “market perform” rating and a $47.00 price objective on the stock. Deutsche Bank Aktiengesellschaft began coverage on Inari Medical in a report on Friday, August 9th. They set a “buy” rating and a $68.00 price target for the company. Truist Financial boosted their price objective on Inari Medical from $46.00 to $50.00 and gave the company a “hold” rating in a research note on Tuesday, October 29th. Piper Sandler raised their target price on Inari Medical from $50.00 to $52.00 and gave the stock a “neutral” rating in a research note on Tuesday, October 29th. Finally, Stifel Nicolaus started coverage on Inari Medical in a report on Tuesday, September 17th. They issued a “hold” rating and a $50.00 target price for the company. Six investment analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $58.89.

Inari Medical Profile

Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.